86 related articles for article (PubMed ID: 20836672)
1. Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics.
Katoh M
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1375-9. PubMed ID: 20836672
[TBL] [Abstract][Full Text] [Related]
2. FGF receptors: cancer biology and therapeutics.
Katoh M; Nakagama H
Med Res Rev; 2014 Mar; 34(2):280-300. PubMed ID: 23696246
[TBL] [Abstract][Full Text] [Related]
3. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate.
Shiang CY; Qi Y; Wang B; Lazar V; Wang J; Fraser Symmans W; Hortobagyi GN; Andre F; Pusztai L
Breast Cancer Res Treat; 2010 Oct; 123(3):747-55. PubMed ID: 20024612
[TBL] [Abstract][Full Text] [Related]
4. FGF signaling network in the gastrointestinal tract (review).
Katoh M; Katoh M
Int J Oncol; 2006 Jul; 29(1):163-8. PubMed ID: 16773196
[TBL] [Abstract][Full Text] [Related]
5. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis.
Dey JH; Bianchi F; Voshol J; Bonenfant D; Oakeley EJ; Hynes NE
Cancer Res; 2010 May; 70(10):4151-62. PubMed ID: 20460524
[TBL] [Abstract][Full Text] [Related]
6. MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands.
McLeskey SW; Ding IY; Lippman ME; Kern FG
Cancer Res; 1994 Jan; 54(2):523-30. PubMed ID: 7506125
[TBL] [Abstract][Full Text] [Related]
7. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
[TBL] [Abstract][Full Text] [Related]
8. Cancer genomics and genetics of FGFR2 (Review).
Katoh M
Int J Oncol; 2008 Aug; 33(2):233-7. PubMed ID: 18636142
[TBL] [Abstract][Full Text] [Related]
9. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer.
Nakamura K; Yashiro M; Matsuoka T; Tendo M; Shimizu T; Miwa A; Hirakawa K
Gastroenterology; 2006 Nov; 131(5):1530-41. PubMed ID: 17101326
[TBL] [Abstract][Full Text] [Related]
10. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
Manuvakhova M; Thottassery JV; Hays S; Qu Z; Rentz SS; Westbrook L; Kern FG
Oncogene; 2006 Sep; 25(44):6003-14. PubMed ID: 16682955
[TBL] [Abstract][Full Text] [Related]
11. Different abilities of the four FGFRs to mediate FGF-1 translocation are linked to differences in the receptor C-terminal tail.
Sørensen V; Wiedlocha A; Haugsten EM; Khnykin D; Wesche J; Olsnes S
J Cell Sci; 2006 Oct; 119(Pt 20):4332-41. PubMed ID: 17003104
[TBL] [Abstract][Full Text] [Related]
12. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
[TBL] [Abstract][Full Text] [Related]
13. FGF receptor phosphotyrosine 766 is a target for Grb14 to inhibit MDA-MB-231 human breast cancer cell signaling.
Cailliau K; Perdereau D; Lescuyer A; Chen H; Garbay C; Vilain JP; Burnol AF; Browaeys-Poly E
Anticancer Res; 2005; 25(6B):3877-82. PubMed ID: 16309174
[TBL] [Abstract][Full Text] [Related]
14. Structural Alterations in Human Fibroblast Growth Factor Receptors in Carcinogenesis.
Mikhaylenko DS; Alekseev BY; Zaletaev DV; Goncharova RI; Nemtsova MV
Biochemistry (Mosc); 2018 Aug; 83(8):930-943. PubMed ID: 30208830
[TBL] [Abstract][Full Text] [Related]
15. Targeting of suicide gene delivery in pancreatic cancer cells via FGF receptors.
Kleeff J; Fukahi K; Lopez ME; Friess H; Büchler MW; Sosnowski BA; Korc M
Cancer Gene Ther; 2002 Jun; 9(6):522-32. PubMed ID: 12032663
[TBL] [Abstract][Full Text] [Related]
16. Cellular signaling by fibroblast growth factor receptors.
Eswarakumar VP; Lax I; Schlessinger J
Cytokine Growth Factor Rev; 2005 Apr; 16(2):139-49. PubMed ID: 15863030
[TBL] [Abstract][Full Text] [Related]
17. FGF and FGFR signaling in chondrodysplasias and craniosynostosis.
Marie PJ; Coffin JD; Hurley MM
J Cell Biochem; 2005 Dec; 96(5):888-96. PubMed ID: 16149058
[TBL] [Abstract][Full Text] [Related]
18. De-regulated FGF receptors as therapeutic targets in cancer.
Knights V; Cook SJ
Pharmacol Ther; 2010 Jan; 125(1):105-17. PubMed ID: 19874848
[TBL] [Abstract][Full Text] [Related]
19. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
[TBL] [Abstract][Full Text] [Related]
20. The role of fibroblast growth factors and their receptors in prostate cancer.
Kwabi-Addo B; Ozen M; Ittmann M
Endocr Relat Cancer; 2004 Dec; 11(4):709-24. PubMed ID: 15613447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
